{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:22:23Z","timestamp":1787584943649,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In this multicenter retrospective cohort study of 135 people with aquaporin\u20104 IgG+ neuromyelitis optica spectrum disorder (NMOSD), some of whom were exposed to multiple therapies, we evaluated the effectiveness and tolerability of rituximab (<jats:italic>n<\/jats:italic>\u2009=\u2009111) and novel monoclonal antibodies (nMAbs): eculizumab (<jats:italic>n<\/jats:italic>\u2009=\u20099), inebilizumab (<jats:italic>n<\/jats:italic>\u2009=\u200923), and satralizumab (<jats:italic>n<\/jats:italic>\u2009=\u200914). Over a median follow\u2010up of 3.92\u2009years, 21\/111 rituximab\u2010treated patients relapsed. In contrast, relapse occurred in only 1\/23 inebilizumab\u2010treated patients (median follow\u2010up 1.27 years), with no relapses observed in those receiving eculizumab or satralizumab. Twelve\u2010month relapse\u2010free probabilities were 92% (rituximab), 94% (inebilizumab), and 100% (eculizumab and satralizumab). Among those with\u00a0available MRI data, 10\/73 rituximab and 1\/14 inebilizumab developed new lesions.\u00a0There were no serious adverse events. These findings support nMAbs as effective and well\u2010tolerated first\u2010line therapies for NMOSD.<\/jats:p>","DOI":"10.1002\/acn3.70160","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:35:26Z","timestamp":1755851726000},"page":"2152-2157","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4097-3421","authenticated-orcid":false,"given":"Zarmina","family":"Javed","sequence":"first","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research Neurological Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6283-1990","authenticated-orcid":false,"given":"Mengke","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Rensel","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research Neurological Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le H.","family":"Hua","sequence":"additional","affiliation":[{"name":"Lou Ruvo Center for Brain Health Las Vegas Cleveland Clinic  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie M.","family":"Hersh","sequence":"additional","affiliation":[{"name":"Lou Ruvo Center for Brain Health Las Vegas Cleveland Clinic  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Abbatemarco","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research Neurological Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon S.","family":"Conway","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research Neurological Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ontaneda","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research Neurological Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research Neurological Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-6491","authenticated-orcid":false,"given":"Amy","family":"Kunchok","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research Neurological Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26049"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696387"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31817\u20103"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(20)30078\u20108"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_2_9_8_1","article-title":"Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults With Anti\u2010Aquaporin\u20104 Antibody Positive Neuromyelitis Optica Spectrum Disorder During the Phase 3 CHAMPION\u2010NMOSD Trial","volume":"5","author":"Pittock S. J.","year":"2023","journal-title":"AAN Meeting"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105502"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209970"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209888"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010018\u20100805\u2010y"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101868"},{"key":"e_1_2_9_16_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1166490"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102166"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2018.11.022"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000061"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104938"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:21:51Z","timestamp":1760404911000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/acn3.70160"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70160","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2025-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}